SCM Lifescience Co., Ltd.

298060· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩2,600+2.16%

2026-08-04

Financials

Valuation Metrics

SCM Lifescience Co., Ltd.'s Market Cap is ₩251B. At end of 2025 it was ₩488B. Ranked #2179 of 2,436 in KR market (top 89%), #1411 of 1,649 on KOSDAQ (top 86%), #219 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	25.06B KRW	KR#2,179/2,436 Sec#219/234
Revenue	38.51B KRW	KR#1,919/2,436 Sec#133/234
Net Income	-91.3M KRW	KR—/2,436 Sec—/234
Total Assets	50.98B KRW	KR#2,185/2,436 Sec#196/234
Net Assets	34.24B KRW	KR#2,113/2,436 Sec#183/234
Employees	56	KR#1,982/2,436 Sec#176/234
Value
P/B	0.73x	KR#1,181/2,436 Sec#66/234
P/S	0.65x	KR#1,107/2,436 Sec#52/234
FCF Yield	-39.48%	KR—/2,436 Sec—/234
Profitability
ROE	-0.27%	KR#1,510/2,436 Sec#105/234
ROA	-0.18%	KR#1,504/2,436 Sec#104/234
Op. Margin	-11.69%	KR#2,014/2,436 Sec#136/234
Revenue Growth	2557.59%	KR#2/2,436 Sec#2/234
Financial Health
Debt Ratio	148.90%	KR#1,172/2,436 Sec#135/234
Total Debt	3.90B KRW	KR#1,822/2,436 Sec#175/234
FCF	-9.89B KRW	KR#1,711/2,436 Sec#148/234
Cash	230.8M KRW	KR#2,387/2,436 Sec#230/234
Current Ratio	2.06x	KR#908/2,436 Sec#105/234
Performance
1Y Return	-51.08%	KR#2,100/2,436 Sec#197/234
1M Return	-4.24%	KR#1,322/2,436 Sec#133/234
From 52W High	-68.96%	KR#2,094/2,436 Sec#186/234
1Y MDD	-64.84%	KR#1,685/2,436 Sec#142/234
Trading
Volume	4,789 shares	KR#2,272/2,436 Sec#224/234
Foreign Own.	3.38%	KR—/2,436 Sec—/234
Per Share
EPS	-248 KRW	KR—/2,436 Sec—/234
BPS	3,873 KRW	KR#1,636/2,436 Sec#126/234

Company Info

CEO 김유정

Employees 56

Founded 2014

HQ 인천광역시 연수구, KR

Website www.scmlifescience.com

동사는 2014년 층분리배양법을 기반으로 설립된 줄기세포치료제 연구개발 바이오 기업임. 고순도·고효능 줄기세포치료제를 개발하며, 만성 이식편대숙주질환 2상, 중등증-중증 급성 췌장염 1/2a상, 중등증-중증 아토피 피부염 1/2상 임상시험을 운영 중임. 말레이시아 Duopharma Biotech Berhad와 동남아 4개국 독점 판매권 계약, 한독과 국내 아토피 피부염 기술이전 계약을 체결하며 글로벌 시장 진출을 확대하고 있음. 에스씨엠생명과학는 2014년에 설립되었으며 인천광역시 연수구에 본사를 두고 있습니다.